Why Panel Intelligence? Our Markets Our Services Panel Intelligence Home

Specialties:

Most Popular Reports:

Newest Reports:

Insomnia: Therapeutic Trends in Managed Care

March 2007

 

Deliverable: PowerPoint Presentation

Project Objectives:

Panel Intelligence engaged a panel of experts to understand current and future market for insomnia therapeutics in a amanaged care setting.  Additionally;

§    Determine current status of insomnia therapeutics

§    Identify changes to warning labels

§    Explore impact of generic Ambien

Companies and Products Mentioned in This Report:

Company

Ticker Symbol

Product (s)

Sanofi Aventis

SNY

Ambien® (zolpidem tartrate),

AmbienCR™ (zolpidem tartrate, extended release)

Sepracor

SEPR

Lunesta®  (eszopiclone),

 

King Pharmaceuticals  

KG

Sonata®    (zaleplon)

 

Takeda Pharmaceuticals

TKPHF.PK

Rozerem™ (ramelteon)

 

Inclusion Criteria and Respondent Demographics:

n                    51 Medical or Pharmacy Directors for a managed care organization (MCO)

n                    MCO has a pharmacy benefit

n                    Make formulary and purchasing decisions regarding pharmaceutical products

Topics Covered:

§       Insomnia on formulary and coverage by brand

§       Changes in formulary status

§       Co-payments by formulary tiers

§       Reactions to label change

§       Expected formulary changes and status of generic Ambien

Download this report

 

 

> about us      > contact us
© Panel Intelligence, LLC. 1999-2008. All rights reserved.
A wholly owned subsidiary of MCF Corporation (NASDAQ: MERR)
Privacy Policy